Clinical Trial Update: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ARGX-113 for safety, efficacy, and pharmacokinetics in adults with primary immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• ARGX-113

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia | Phase 2 | Status: COMPLETED